News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH COVID-19 VACCINE (BNT162b2) IN HIGH-RISK INDIVIDUALS

Study Status:

Open For Enrollment

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The objective of the study is to determine the effectiveness of a 3rd dose and/or 4th Dose in the prevention of SARS-CoV-2 infections and determine the anti-SARS-CoV-2 IgG antibody titers using a semi quantitative 2. method at various time points (Baseline/Day0, Day14, Week12 and Week 24 after booster)

Information: 

Principal Investigator
Sohail Rao, MD
Sponsor
DHR Health Institute for Research and Development
Type of Trial
Interventional
© 2022 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram